Myocardial dysfunction in severe sepsis and septic shock: No correlation with inflammatory cytokines in real-life clinical setting

Chest

Volumn 148, Issue 1, 2015, Pages 93-102

  Landesberg, Giora ^a   Levin, Phillip D ^a   Gilon, Dan ^a   Goodman, Sergey ^a   Georgieva, Milena ^a   Weissman, Charles ^a   Jaffe, Allan S ^b   Sprung, Charles L ^a   Barak, Vivian ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HYPERTENSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN DERIVATIVE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; APACHE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; FLUID BALANCE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART STROKE VOLUME; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MYOCARDIAL DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; SEPTIC SHOCK; SYSTOLIC DYSFUNCTION; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; URINE VOLUME; AGED; BLOOD; COHORT ANALYSIS; COMPLICATION; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; MIDDLE AGED; MORTALITY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHEMOKINE CCL2; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SHOCK, SEPTIC; STROKE VOLUME; TROPONIN T; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84937570546     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2259     Document Type: Article

References (36)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138-150.
2. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100(4):483-490.
3. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest. 1985;76(4):1539-1553.
4. Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care. 2002;8(5):376-388.
5. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med. 2007;35(6):1599-1608.
6. Pathan N, Sandiford C, Harding SE, Levin M. Characterization of a myocardial depressant factor in meningococcal septicemia. Crit Care Med. 2002;30(10):2191-2198.
7. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257(5068):387-389.
8. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-α and interleukin-1beta synergistically depress human myocardial function. Crit Care Med. 1999;27(7):1309-1318.
9. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183(3):949-958.
10. Raeburn CD, Dinarello CA, Zimmerman MA, et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol. 2002;283(2):H650-H657.
11. Tavener SA, Kubes P. Cellular and molecular mechanisms underlying LPS-associated myocyte impairment. Am J Physiol Heart Circ Physiol. 2006;290(2):H800-H806.
12. Pathan N, Franklin JL, Eleftherohorinou H, et al. Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase. Crit Care Med. 2011;39(7):1692-1711.
13. Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004;363(9404):203-209.
14. Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J. 2012;33(7):895-903.
15. Landesberg G, Jaffe AS, Gilon D, et al. Troponin elevation in severe sepsis and septic shock: the role of left ventricular diastolic dysfunction and right ventricular dilatation. Crit Care Med. 2014;42(4):790-800.
16. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.
17. Dellinger RP, Levy MM, Carlet JM, et al International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327.
18. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539-2550.
19. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22(2):107-133.
20. Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM. TNF-alpha and IL-1beta increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium. 2010;47(4):378-386.
21. Kao YH, Chen YC, Cheng CC, Lee TI, Chen YJ, Chen SA. Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med. 2010;38(1):217-222.
22. Werdan K, Müller-Werdan U. Elucidating molecular mechanisms of septic cardiomyopathy - the cardiomyocyte model. Mol Cell Biochem. 1996;163-164:291-303.
23. Bouhemad B, Nicolas-Robin A, Arbelot C, Arthaud M, Féger F, Rouby JJ. Isolated and reversible impairment of ventricular relaxation in patients with septic shock. Crit Care Med. 2008;36(3):766-774.
24. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27(7):1230-1251.
25. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care Med. 1997;25(8):1298-1307.
26. Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11(2):R49.
27. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988;319(7):397-400.
28. Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med. 1989;17(6):489-494.
29. Fisher CJ Jr, Agosti JM, Opal SM, et al The Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med. 1996;334(26):1697-1702.
30. Opal SM, Cross AS, Jhung JW, et al. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J Infect Dis. 1996;173(6):1415-1421.
31. Reynolds CM, Suliman HB, Hollingsworth JW, Welty-Wolf KE, Carraway MS, Piantadosi CA. Nitric oxide synthase-2 induction optimizes cardiac mitochondrial biogenesis after endotoxemia. Free Radic Biol Med. 2009;46(5):564-572.
32. Bougaki M, Searles RJ, Kida K, Yu J, Buys ES, Ichinose F. Nos3 protects against systemic inflammation and myocardial dysfunction in murine polymicrobial sepsis. Shock. 2010;34(3):281-290.
33. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36(6):1701-1706.
34. Bergmann M, Gornikiewicz A, Sautner T, et al. Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis. Shock. 1999;12(6):421-427.
35. Muthu K, Deng J, Gamelli R, Shankar R, Jones SB. Adrenergic modulation of cytokine release in bone marrow progenitor-derived macrophage following polymicrobial sepsis. J Neuroimmunol. 2005;158(1-2):50-57.
36. Repessé X, Charron C, Vieillard-Baron A. Evaluation of left ventricular systolic function revisited in septic shock. Crit Care. 2013;17(4):164-166.